DENVER, June 22 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that Michael Gerber, M.D., Senior Vice
President, Clinical Development and Regulatory Affairs, will participate in
the Punk Ziegel Investor Symposium "New Developments in the Treatment of
Pulmonary Arterial Hypertension (PAH)."
The symposium will take place from 10:00 a.m. to 3:00 p.m. (Eastern) on
Tuesday, June 22, 2004. There will be a live webcast of the symposium, which
will be accessible through a link posted on the investor relations section of
the Myogen website at http://investor.myogen.com/. The webcast will be
available for replay on Myogen's website through July 2, 2004.
Myogen currently markets one product in Europe for the treatment of acute
decompensated heart failure and has three product candidates in late-stage
clinical development: enoximone capsules for the treatment of chronic heart
failure, ambrisentan for the treatment of pulmonary arterial hypertension and
darusentan for the treatment of resistant hypertension. The Company, in
collaboration with Novartis, also conducts a target and drug discovery
research program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com.
Safe Harbor Statement
This press release and the anticipated presentation contain forward-
looking statements that involve significant risks and uncertainties, including
those discussed in this release, those to be discussed in the presentation and
others that can be found in the "Risk Factors" section of Myogen's Form 10-K
for the year ended December 31, 2003 and in Myogen's periodic reports on Form
10-Q and Form 8-K. Myogen does not undertake any obligation to update any
forward-looking statements contained in this document or the anticipated
presentation as a result of new information, future events or otherwise. The
Company cautions investors not to place undue reliance on the forward-looking
statements contained in this press release or the presentation. No
forward-looking statement can be guaranteed and actual events and results may
differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
